JP6891173B2 - Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いたｍｓの治療方法 - Google Patents

Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いたｍｓの治療方法 Download PDF

Info

Publication number
JP6891173B2
JP6891173B2 JP2018525702A JP2018525702A JP6891173B2 JP 6891173 B2 JP6891173 B2 JP 6891173B2 JP 2018525702 A JP2018525702 A JP 2018525702A JP 2018525702 A JP2018525702 A JP 2018525702A JP 6891173 B2 JP6891173 B2 JP 6891173B2
Authority
JP
Japan
Prior art keywords
compound
substituted
het
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018525702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538264A (ja
JP2018538264A5 (enExample
Inventor
デロベイド タミー
デロベイド タミー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2018538264A publication Critical patent/JP2018538264A/ja
Publication of JP2018538264A5 publication Critical patent/JP2018538264A5/ja
Application granted granted Critical
Publication of JP6891173B2 publication Critical patent/JP6891173B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2018525702A 2015-11-17 2016-11-16 Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いたｍｓの治療方法 Active JP6891173B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562256199P 2015-11-17 2015-11-17
US62/256,199 2015-11-17
PCT/US2016/062154 WO2017087445A1 (en) 2015-11-17 2016-11-16 Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity

Publications (3)

Publication Number Publication Date
JP2018538264A JP2018538264A (ja) 2018-12-27
JP2018538264A5 JP2018538264A5 (enExample) 2019-12-26
JP6891173B2 true JP6891173B2 (ja) 2021-06-18

Family

ID=57460611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525702A Active JP6891173B2 (ja) 2015-11-17 2016-11-16 Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いたｍｓの治療方法

Country Status (26)

Country Link
US (2) US10716788B2 (enExample)
EP (2) EP3377484B1 (enExample)
JP (1) JP6891173B2 (enExample)
KR (1) KR102780243B1 (enExample)
CN (1) CN108884076B (enExample)
AU (1) AU2016357735B2 (enExample)
BR (1) BR112018007517B1 (enExample)
CL (1) CL2018001252A1 (enExample)
DK (1) DK3377484T3 (enExample)
ES (1) ES2964946T3 (enExample)
FI (1) FI3377484T3 (enExample)
HR (1) HRP20231547T1 (enExample)
HU (1) HUE064244T2 (enExample)
IL (1) IL258978B (enExample)
LT (1) LT3377484T (enExample)
MX (1) MX386146B (enExample)
MY (1) MY199473A (enExample)
NZ (1) NZ741294A (enExample)
PH (1) PH12018500736A1 (enExample)
PL (1) PL3377484T3 (enExample)
PT (1) PT3377484T (enExample)
RS (1) RS64908B1 (enExample)
SI (1) SI3377484T1 (enExample)
UA (1) UA123159C2 (enExample)
WO (1) WO2017087445A1 (enExample)
ZA (1) ZA201802348B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001735A1 (en) * 2015-11-04 2017-05-11 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
CN108884076B (zh) * 2015-11-17 2021-07-30 默克专利有限公司 使用具有btk抑制活性的嘧啶和吡啶化合物治疗多发性硬化症的方法
KR20210022674A (ko) * 2018-06-19 2021-03-03 메르크 파텐트 게엠베하 1-(4-｛[6-아미노-5-(4-페녹시-페닐)-피리미딘-4-일아미노]-메틸｝-4-플루오로-피페리딘-1-일)-프로펜온의 신규한 결정 형태, 이의 염 형태, 및 이를 수득하는 방법
HRP20241737T1 (hr) * 2018-07-20 2025-02-28 Merck Patent Gmbh Supstituirani amino-pirimidinski spoj za upotrebu u postupku za liječenje i prevenciju multiple skleroze
IL294560A (en) 2020-01-20 2022-09-01 Genzyme Corp Medicinal tyrosine kinase inhibitors for relapsing multiple sclerosis
CN112250666B (zh) * 2020-10-09 2022-01-14 广东东阳光药业有限公司 取代的嘧啶类化合物及其用途
CA3200332A1 (en) * 2020-12-02 2022-06-09 Telios Pharma, Inc. Methods and compositions for treating an ophthalmic condition
WO2022121670A1 (zh) 2020-12-10 2022-06-16 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
CN119744171A (zh) 2022-06-24 2025-04-01 默克专利股份公司 自身免疫病和炎性疾病的治疗方案
WO2024099241A1 (zh) * 2022-11-07 2024-05-16 天津征程医药科技有限公司 氘代的嘧啶衍生物以及包含该化合物的药物组合物
WO2025096900A1 (en) * 2023-11-03 2025-05-08 Board Of Regents, The University Of Texas System Synthetic network materials and methods of making and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
CN101676285A (zh) 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
GB0512844D0 (en) * 2005-06-23 2005-08-03 Novartis Ag Organic compounds
ES2673973T3 (es) * 2006-09-22 2018-06-26 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
US20100311736A1 (en) * 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2011029804A1 (en) 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibitors of jak
KR101301533B1 (ko) 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
PT2718270T (pt) 2011-06-10 2022-07-29 Merck Patent Gmbh Composições e métodos para a produção de compostos de pirimidina e piridina com atividade inibidora de btk
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
GEP201606597B (en) * 2012-11-02 2017-01-10 Pfizer Bruton's tyrosine kinase inhibitors
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US9598398B2 (en) * 2013-04-04 2017-03-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
BR112015032330B1 (pt) * 2013-06-26 2019-01-22 Abbvie Inc. carboxamidas primárias como inibidores de bkt
SG11201600159TA (en) * 2013-07-31 2016-02-26 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
KR20160058889A (ko) 2013-09-22 2016-05-25 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
CA3001735A1 (en) * 2015-11-04 2017-05-11 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
CN108884076B (zh) * 2015-11-17 2021-07-30 默克专利有限公司 使用具有btk抑制活性的嘧啶和吡啶化合物治疗多发性硬化症的方法

Also Published As

Publication number Publication date
LT3377484T (lt) 2023-12-27
PT3377484T (pt) 2023-12-14
IL258978B (en) 2021-04-29
US10716788B2 (en) 2020-07-21
BR112018007517A2 (pt) 2018-10-23
CA3002224A1 (en) 2017-05-26
CN108884076A (zh) 2018-11-23
FI3377484T3 (fi) 2023-11-30
EP4295910A2 (en) 2023-12-27
EP4295910A3 (en) 2024-03-20
BR112018007517B1 (pt) 2023-09-26
KR20180080243A (ko) 2018-07-11
JP2018538264A (ja) 2018-12-27
PL3377484T3 (pl) 2024-04-08
US20170136018A1 (en) 2017-05-18
DK3377484T3 (da) 2023-11-27
MX386146B (es) 2025-03-18
ES2964946T3 (es) 2024-04-10
MY199473A (en) 2023-10-31
EP3377484B1 (en) 2023-09-06
UA123159C2 (uk) 2021-02-24
HRP20231547T1 (hr) 2024-03-15
AU2016357735A1 (en) 2018-04-26
PH12018500736A1 (en) 2018-10-01
RS64908B1 (sr) 2023-12-29
WO2017087445A1 (en) 2017-05-26
MX2018005463A (es) 2018-08-01
AU2016357735B2 (en) 2021-01-14
KR102780243B1 (ko) 2025-03-14
EP3377484A1 (en) 2018-09-26
ZA201802348B (en) 2020-08-26
US20200316068A1 (en) 2020-10-08
CL2018001252A1 (es) 2018-08-17
SI3377484T1 (sl) 2024-02-29
NZ741294A (en) 2023-07-28
IL258978A (en) 2018-07-31
CN108884076B (zh) 2021-07-30
RU2018120151A3 (enExample) 2020-03-24
RU2018120151A (ru) 2019-12-18
HUE064244T2 (hu) 2024-02-28

Similar Documents

Publication Publication Date Title
JP6891173B2 (ja) Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いたｍｓの治療方法
JP7295169B2 (ja) Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法
US12071424B2 (en) IRE1 small molecule inhibitors
CN115843272B (zh) Nek7激酶的抑制剂
US10513521B2 (en) Compositions and methods for inhibiting BMP
JP7034512B2 (ja) キナーゼ阻害剤としてのヘテロアリール化合物
AU2012223720A1 (en) 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
EA016969B1 (ru) 1,3-двузамещенные-4-фенил-1н-пиридин-2-оны
JP2010533203A (ja) 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
US20150274708A1 (en) Inhibitors of irak4 activity
RS63418B1 (sr) Kompozicije i metode za proizvodnju jedinjenja pirimidina i piridina sa btk inhibitorskom aktivnošću
JP2021098691A (ja) 核内受容体に対して活性の化合物
TWI565698B (zh) 喹啉化合物，其製造方法及用途
KR20160040301A (ko) 증식성 질환의 치료를 위한 １ｈ― 피라졸로［3,4―ｂ］피리딘의 유도체 및 그의 약학 조성물
CA3119399A1 (en) Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta
CN119384408A (zh) 用于靶向蛋白降解的双功能分子
WO2023230500A1 (en) Spleen tyrosine kinase inhibitors and methods of use thereof
RU2779287C2 (ru) Способы лечения рассеянного склероза с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
HK40108018A (zh) 作为kv7.2抑制剂的新型杂芳基脲化合物
HK1262555A1 (en) Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
WO2022062601A1 (zh) 嘧啶并吡咯类化合物
HK1255833B (en) Hpk1 inhibitors and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210526

R150 Certificate of patent or registration of utility model

Ref document number: 6891173

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250